Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 18/20 | 0.62 |
| ▸ | TDO2 | P48775 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29609391 | 1.00 | IDO1 (0.62) | IDO1TDO2POLBHPGD | |
| SCHEMBL149915 | 1.00 | IDO1 (0.62) | IDO1TDO2POLBHPGD | |
| SCHEMBL149916 | 1.00 | IDO1 (0.62) | IDO1TDO2POLBHPGD | |
| SCHEMBL2520519 | 0.90 | IDO1 (0.53) | IDO1TDO2POLBHPGD | |
| SCHEMBL2520514 | 0.90 | IDO1 (0.53) | IDO1TDO2POLBHPGD | |
| SCHEMBL22062670 | 0.89 | IDO1 (0.61) | IDO1TDO2POLBHPGD | |
| SCHEMBL21118296 | 0.88 | IDO1 (0.50) | IDO1TDO2POLBHPGD | |
| SCHEMBL2516714 | 0.88 | IDO1 (0.50) | IDO1TDO2POLBHPGD | |
| SCHEMBL2516716 | 0.88 | IDO1 (0.50) | IDO1TDO2POLBHPGD | |
| SCHEMBL20090741 | 0.87 | IDO1 (0.52) | IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3389783-B1 | NOVEL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-3389783-B1 | NOVEL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-111943906-B | Amidine derivatives, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2023-12-15 | — | — | CN | disclosed |
| CN-115073442-A | Disulfide bond-containing compound, preparation method thereof, pharmaceutical composition and application | 中国医学科学院药物研究所 | 2022-09-20 | — | — | CN | disclosed |
| CN-108530444-B | Novel NAMPT and IDO dual inhibitor and preparation method and medical application thereof | 药康众拓(江苏)医药科技有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-11014895-B2 | Heterocyclic urea compound, and drug composition and application thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2021-05-25 | — | — | US | disclosed |
| EP-3744715-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | Incyte Holdings Corporation (US) | 2020-12-02 | — | — | EP | disclosed |
| CN-111943906-A | Amidine derivative, preparation method thereof, pharmaceutical composition and application | 中国医学科学院药物研究所 | 2020-11-17 | — | — | CN | disclosed |
| EP-3677581-A1 | DEUTERATED INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR AND APPLICATION THEREOF | Nanjing Transthera Biosciences Co. Ltd. (CN) | 2020-07-08 | — | — | EP | disclosed |
| EP-3066085-B1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2020-05-13 | — | — | EP | disclosed |
| WO-2017106062-A1 | NOVEL COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | WO | disclosed |
| US-9624185-B1 | Method for preparing IDO inhibitor epacadostat | XU YONG (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624185-B1 | Method for preparing IDO inhibitor epacadostat | XU YONG (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160221996-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION | 2016-08-04 | — | — | US | disclosed |
| US-20160221996-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION | 2016-08-04 | — | — | US | disclosed |
| US-9321755-B2 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | INCYTE CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321755-B2 | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | INCYTE CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| WO-2015070007-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20150133674-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION (US) | 2015-05-14 | — | — | US | disclosed |
| US-20150133674-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | INCYTE CORPORATION (US) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133674-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | IDO1, INMT, IDO2 | IDO1 1/4885TDO2 6/4885POLB 2652/4885 |
| US-20160221996-A1 | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR | IDO1, INMT, IDO2 | IDO1 1/4885TDO2 6/4885POLB 2652/4885 |
| US-11014895-B2 | Heterocyclic urea compound, and drug composition and application thereof | IDO1, IDO2, INMT | IDO1 1/4885TDO2 21/4885POLB 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.